All In Biotech

Drug Trial Radar · NCT07744386

A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol

An Open-label, Fixed-sequence, Non-randomized, Drug-drug Interaction Study to Evaluate the Effect of CHF10196 on the Pharmacokinetics of Dabigatran (P-gp Substrate) and Rosuvastatin (BCRP Substrate) in Healthy Male Participants.

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Dec 15, 2028

Study completion Dec 15, 2028

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a breast cancer resistant protein substrate) in healthy male participants.

Conditions

  • Healthy Male Volunteers

Interventions

  • Dabigatran EtexilateDrug

    Treatment period 1: Single dose administered on Day 1; Treatment period 2: Single dose administered on Day 13

  • RosuvastatinDrug

    Treatment period 1: Single dose administered on Day 4; Treatment period 2: Single dose administered on Day 16

  • CHF10196Drug

    Treatment period 2: Single dose administered daily from Day 8 to Day 19

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics of Dabigatran : AUC0-tTime frame: Up to 72 hours after dosing
  2. Pharmacokinetics of Dabigatran: AUC0-∞Time frame: Up to 72 hours after dosing
  3. Pharmacokinetics of Dabigatran: CmaxTime frame: Up to 72 hours after dosing
  4. Pharmacokinetics of Rosuvastatin :AUC0-tTime frame: Up to 96 hours after dosing
  5. Pharmacokinetics of Rosuvastatin : AUC0-∞Time frame: Up to 96 hours after dosing
  6. Pharmacokinetics of Rosuvastatin: CmaxTime frame: Up to 96 hours after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit (CRU) Limited

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.